Medico Remedies Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Profit growth above 25%Revenue growth above 20%Auditor changed mid-yearResults View source PDF Explain this filing

MEDICO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.6%Reaction day

₹46.53

prior close

₹47.45

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+0.5% vs market

Pharmaceuticals peers, median of 164sector-0.1%+0.7% vs sector

On the reaction day the stock moved 0.5 pts more than Nifty Microcap 250 and 0.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.2

10m

-1.5

15m

-1.6

30m

-1.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.6+0.1+0.5-0.1+0.7

Next day

+5.2+1.7+3.5+0.9+4.3

+4.0+2.4+1.6+0.9+3.1

+5.3+2.4+2.9+0.7+4.6

+3.0+1.7+1.3+0.8+2.2

+1.9+0.6+1.3+0.0+1.9

-0.2+1.9-2.1-0.0-0.2

15d

-10.2+4.9-15.1+1.2-11.3

-9.5+8.9-18.4+3.0-12.5

-17.5+7.5-25.0+4.7-22.2

-9.7+13.6-23.3+7.9-17.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Medico Remedies Limited reported strong annual performance for FY2026 ending March 31, 2026. Revenue from operations grew 36.85% to Rs. 20,637.73 lakhs from Rs. 15,094.06 lakhs in FY2025. Net profit after tax increased 30.04% to Rs. 1,312.52 lakhs from Rs. 1,009.32 lakhs year-over-year. The company manufactures pharmaceutical formulations and exports form a significant portion of sales. The statutory auditor Shah Shroff & Associates issued an unmodified opinion on the financial statements, indicating no concerns. Q4 standalone revenue was Rs. 5,680.77 lakhs with net profit of Rs. 585.66 lakhs. The auditor was changed from V J Shah & Co (previous auditor) to Shah Shroff & Associates for this period.

Likely market impact

Positive signal for shareholders as the company delivered robust revenue and profit growth exceeding 25%. Clean audit opinion with no going concern issues provides assurance on financial health, though EBITDA margin showed slight compression.